Yes, sorafenib is used for kidney cancer, specifically advanced renal cell carcinoma (RCC).[1]
How sorafenib treats kidney cancer
Sorafenib (brand name Nexavar) is a multikinase inhibitor that blocks enzymes involved in tumor cell growth and blood vessel formation. The FDA approved it in 2005 for advanced RCC in patients who failed prior interferon-alpha or interleukin-2 therapy, based on phase 3 trials showing it prolonged progression-free survival compared to placebo.[1][2] It's taken orally as 400 mg tablets twice daily.
Common use in practice today
Guidelines from the National Comprehensive Cancer Network (NCCN) list sorafenib as a later-line option for advanced or metastatic clear cell RCC, often after immunotherapy or other tyrosine kinase inhibitors like sunitinib.[3] It's less common as first-line due to newer agents like cabozantinib or nivolumab plus ipilimumab.
When doctors prescribe it for kidneys
Typically for patients with progressive disease after initial treatments, or those ineligible for preferred therapies. Combination regimens, like sorafenib with immunotherapy, are under study but not standard.[3]
Key side effects patients report
Hand-foot skin reaction (redness, pain on palms/soles), diarrhea, fatigue, hypertension, and rash occur in over 20% of users. Dose reductions happen in about 40% of cases; rare but serious risks include bleeding and heart issues.[1][2]
How it compares to other kidney cancer drugs
| Drug | First-line preference | Key difference from sorafenib |
|------|-----------------------|-------------------------------|
| Sunitinib (Sutent) | Higher | Similar PFS benefit but more fatigue; often first choice historically. |
| Cabozantinib (Cabometyx) | Higher | Better overall survival in trials; stronger against MET/AXL pathways. |
| Nivolumab + ipilimumab | Highest | Immunotherapy combo; superior OS but higher immune-related toxicity. |
Sorafenib's role has shifted to second- or third-line amid these advances.[3]
Who makes sorafenib and patent status
Bayer and Onyx Pharmaceuticals developed Nexavar. Key U.S. patents expired around 2020-2022, enabling generics; check DrugPatentWatch.com for latest expiry details and litigation on remaining formulations.[4]
Sources
[1]: FDA Label for Nexavar
[2]: NEJM: Sorafenib in Advanced Clear-Cell RCC (2007)
[3]: NCCN Guidelines: Kidney Cancer (v.2.2024)
[4]: DrugPatentWatch.com: Sorafenib Patents